Advanced RCC: dalantercept shows promise in phase 2 trial

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • Dalantercept plus axitinib (Inlyta) demonstrated a favorable safety profile and clinically meaningful antitumor activity in patients with previously treated renal cell carcinoma (RCC).

Why this matters

 

 

  • Dual angiogenic blockade is appealing considering the limited duration of activity of vascular endothelial growth factor (VEGF) inhibitors due to the development of resistance.

 

Key results

  • 62% of participants had ≥2 prior therapies. 
  • No dose-limiting toxicities, grade 4/5 drug-related adverse events (AEs), or serious bleeding in dose-escalation cohorts. 
  • Common treatment-emergent AEs included fatigue, diarrhea, peripheral edema, nausea, increased creatinine, epistaxis, pericardial effusion, and telangiectasias. 
  • Pericardial and pleural effusions occurred in 21% and 14%, respectively, and were deemed to be possibly related to dalantercept. 
  • 7 (25.0%) patients achieved partial response, 17 (60.7%) had stable disease, and 4 (14.3%) had progressive disease as best response. 
  • No patients achieved complete response. 
  • Median PFS was 8.3 mo. 
  • After cycle 1, there was a 73% mean reduction in VEGFR3 compared with baseline (P<.001).

Study design

  • Open-label phase 2 trial of dalantercept 0.6 (n=6), 0.9 (n=4), or 1.2 mg/kg (n=5) subcutaneously every 3 wk plus axitinib 5 mg twice-daily in 29 patients assigned to dose-escalation (n=15) and expansion (n=14) cohorts. 
  • Funding: Acceleron Pharma.

Limitations

  • Small sample. 
  • Open-label.